RAJAF
Cordyceps Sunshine Biotech Holdings Co., Ltd. engages in the cultivation and sale of Chinese rare medicinal herb, taiwanofungus raw material, and finished products in China. The company offers Taiwanofungus Oral pill, a pill form dietary supplement; Taiwanofungus Double A Oral shot, TAIWANOFUNGUS x SALVIA MILTIORRHIZA ORAL Shot, and Collagen Max Drink, a liquid form dietary supplement; and Barbie… Read more
RAJAF (RAJAF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2023: 8.352x
Based on the latest financial reports, RAJAF (RAJAF) has a cash flow conversion efficiency ratio of 8.352x as of December 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.27 Million) by net assets ($-151.80K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
RAJAF - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how RAJAF's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
RAJAF Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of RAJAF ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Smart Eye AB
ST:SEYE
|
0.002x |
|
Tropicana Corporation Bhd
KLSE:5401
|
-0.058x |
|
Ricardo plc
F:RIR
|
0.018x |
|
Shanghai Shibei Hi-Tech Co Ltd B
SHG:900902
|
-0.010x |
|
CviLux Corp
TW:8103
|
0.054x |
|
Adimmune Corp
TW:4142
|
-0.073x |
|
Lotus Resources Ltd
AU:LOT
|
0.006x |
|
Klaveness Combination Carriers ASA
OL:KCC
|
0.060x |
Annual Cash Flow Conversion Efficiency for RAJAF (2021–2024)
The table below shows the annual cash flow conversion efficiency of RAJAF from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-375.54K | $312.01K | -0.831x | +64.94% |
| 2023-12-31 | $-151.80K | $359.72K | -2.370x | -801.50% |
| 2022-12-31 | $-951.33K | $-321.38K | 0.338x | -74.50% |
| 2021-12-31 | $-275.81K | $-365.36K | 1.325x | -- |